Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023890 (
cirrhosis
)
42,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatocarcinogenesis is a multistep process involving progression from
cirrhosis
, to low-grade dysplastic nodule, to high-grade dysplastic nodule (HGDN) and, eventually, to hepatocellular carcinoma (HCC). Early detection of HCC is challenging as the differential diagnosis between HGDN and early HCC (eHCC) is difficult. The aim of the present study was to identify a novel biomarker to specifically differentiate between HGDN and eHCC, which may facilitate early diagnosis of HCC. Immunohistochemistry was performed to determine the expression of
heterogeneous nuclear ribonucleoprotein A3
(
HNRNPA3
) in
cirrhosis
, dysplastic nodules (DNs), well-differentiated HCC and progressed HCC. The staining was evaluated by assigning a staining intensity score of 0-3 and a percentage of positively stained cells score of 0-4. Receiver operator characteristic (ROC) curve analysis was used to assess the ability of
HNRNPA3
expression to differentiate between DNs and HCC.
HNRNPA3
expression increased in a stepwise trend in non-tumor hepatic tissue, DNs, eHCC and progressed HCC. ROC curves revealed that
HNRNPA3
expression could be used to differentiate between HGDN and eHCC, particularly in combination with glypican 3 (GPC3), with a specificity of 100%. Moreover,
HNRNPA3
expression was associated with HCC differentiation. In addition, high expression of
HNRNPA3
was found to be associated with poor survival rates in patients with HCC. These findings demonstrated that
HNRNPA3
combined with GPC3 is a helpful diagnostic biomarker in the differential diagnosis during the multistep process of hepatocarcinogenesis, particularly in the differential diagnosis between HGDN and eHCC. To the best of our knowledge, this is the first study to report the significance of
HNRNPA3
in hepatocarcinogenesis and its potential role in carcinogenesis.
...
PMID:Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesis. 3328 57